Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7301
    +0.0004 (+0.05%)
     

  • CRUDE OIL

    82.71
    -0.10 (-0.12%)
     

  • Bitcoin CAD

    88,029.83
    -3,213.43 (-3.52%)
     

  • CMC Crypto 200

    1,387.94
    -36.16 (-2.54%)
     

  • GOLD FUTURES

    2,331.50
    -6.90 (-0.30%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,463.00
    -201.50 (-1.14%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,769.84
    -690.24 (-1.79%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

RxSight to Report Third Quarter 2021 Financial Results on November 10, 2021

RxSight, Inc.
·1 min read

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.rxsight.com, on the Investors page in the News and Events section. The call will also be available by dialing 844-602-7038 (U.S.) or 916-637-9714 (International) five to ten minutes prior to the start time, using conference ID: 1239025.

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight® can be found at www.rxsight.com.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com

Company contact:
Roy Freeman
Sr. Director, Marketing
rfreeman@rxsight.com